ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Deferred Revenue of -$2.89 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-08-02
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$29.85M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was $26.96M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was $7.89M, a 32.62% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$4.99M, a 251.70% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2017 was $1.85M, a 87.36% decline from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2016 was $14.62M, a 667.59% increase from fiscal 2015.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2015 was $1.90M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2014 was -$7.79M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$29.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$2.89M 10-Q · filed 2018-08-02 | $5.00M derived: sum of 3 quarters · filed 2018-08-02 | $20.00K derived: sum of 4 quarters · filed 2018-08-02 |
| 2018-03-31 | $26.96M 10-Q · filed 2018-05-04 | $34.85M derived: sum of 2 quarters · filed 2018-05-04 | $29.87M derived: sum of 3 quarters · filed 2018-05-04 | $28.94M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $2.91M derived: sum of 2 quarters · filed 2018-02-15 | $1.98M derived: sum of 3 quarters · filed 2018-08-02 | $1.85M 10-K · filed 2018-02-15 |
| 2017-09-30 | -$4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$5.92M derived: sum of 2 quarters · filed 2018-08-02 | -$6.04M 10-Q · filed 2017-11-07 | -$93.00K derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-06-30 | -$931.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$1.06M 10-Q · filed 2018-08-02 | $4.89M derived: sum of 3 quarters · filed 2018-08-02 | $8.18M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | -$128.00K 10-Q · filed 2018-05-04 | $5.82M derived: sum of 2 quarters · filed 2018-05-04 | $9.11M derived: sum of 3 quarters · filed 2018-05-04 | $11.91M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $5.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $9.24M derived: sum of 2 quarters · filed 2018-02-15 | $12.04M derived: sum of 3 quarters · filed 2018-02-15 | $14.62M 10-K · filed 2018-02-15 |
| 2016-09-30 | $3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $6.08M derived: sum of 2 quarters · filed 2017-11-07 | $8.66M 10-Q · filed 2017-11-07 | $11.33M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $5.38M 10-Q · filed 2017-08-09 | $8.05M derived: sum of 3 quarters · filed 2018-02-15 | $11.42M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $2.58M 10-Q · filed 2017-05-05 | $5.25M derived: sum of 2 quarters · filed 2018-02-15 | $8.62M derived: sum of 3 quarters · filed 2018-02-15 | $10.67M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $6.04M derived: sum of 2 quarters · filed 2018-02-15 | $8.09M derived: sum of 3 quarters · filed 2018-02-15 | $1.90M 10-K · filed 2018-02-15 |
| 2015-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $5.42M derived: sum of 2 quarters · filed 2016-11-03 | -$764.00K 10-Q · filed 2016-11-03 | $15.79M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$4.14M 10-Q · filed 2016-08-04 | $12.42M derived: sum of 3 quarters · filed 2017-02-15 | $3.17M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | -$6.19M 10-Q · filed 2016-05-04 | $10.37M derived: sum of 2 quarters · filed 2017-02-15 | $1.11M derived: sum of 3 quarters · filed 2017-02-15 | -$6.13M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $16.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $7.30M derived: sum of 2 quarters · filed 2017-02-15 | $59.00K derived: sum of 3 quarters · filed 2017-02-15 | -$7.79M 10-K · filed 2017-02-15 |
| 2014-09-30 | -$9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$16.50M derived: sum of 2 quarters · filed 2015-11-09 | -$24.34M 10-Q · filed 2015-11-09 | -$23.59M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$7.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$15.09M 10-Q · filed 2015-08-07 | -$14.34M derived: sum of 3 quarters · filed 2016-02-12 | -$20.20M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | -$7.84M 10-Q · filed 2015-05-08 | -$7.09M derived: sum of 2 quarters · filed 2016-02-12 | -$12.95M derived: sum of 3 quarters · filed 2016-02-12 | -$21.28M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $753.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | -$5.11M derived: sum of 2 quarters · filed 2016-02-12 | -$13.44M derived: sum of 3 quarters · filed 2016-02-12 | -$6.20M 10-K · filed 2016-02-12 |
| 2013-09-30 | -$5.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$14.19M derived: sum of 2 quarters · filed 2014-11-06 | -$6.95M 10-Q · filed 2014-11-06 | $9.15M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$8.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$1.09M 10-Q · filed 2014-08-08 | $15.01M derived: sum of 3 quarters · filed 2015-02-13 | $27.74M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $7.24M 10-Q · filed 2014-05-09 | $23.34M derived: sum of 2 quarters · filed 2015-02-13 | $36.08M derived: sum of 3 quarters · filed 2015-02-13 | $18.74M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $16.11M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $28.84M derived: sum of 2 quarters · filed 2015-02-13 | $11.51M derived: sum of 3 quarters · filed 2015-02-13 | -$8.56M 10-K · filed 2015-02-13 |
| 2012-09-30 | $12.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$4.60M derived: sum of 2 quarters · filed 2013-11-07 | -$24.67M 10-Q · filed 2013-11-07 | -$44.35M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | -$17.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$37.40M 10-Q · filed 2013-08-09 | -$57.08M derived: sum of 3 quarters · filed 2014-02-20 | -$77.39M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | -$20.07M 10-Q · filed 2013-05-07 | -$39.75M derived: sum of 2 quarters · filed 2014-02-20 | -$60.06M derived: sum of 3 quarters · filed 2014-02-20 | -$80.43M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | -$19.68M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$39.99M derived: sum of 2 quarters · filed 2014-02-20 | -$60.36M derived: sum of 3 quarters · filed 2014-02-20 | -$70.25M 10-K · filed 2014-02-20 |
| 2011-09-30 | -$20.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | -$40.67M derived: sum of 2 quarters · filed 2012-11-05 | -$50.57M 10-Q · filed 2012-11-05 | -$70.40M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | -$20.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$30.27M 10-Q · filed 2012-08-08 | -$50.09M derived: sum of 3 quarters · filed 2013-02-19 | -$72.22M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | -$9.90M 10-Q · filed 2012-05-03 | -$29.73M derived: sum of 2 quarters · filed 2013-02-19 | -$51.85M derived: sum of 3 quarters · filed 2013-02-19 | -$70.93M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | -$19.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | -$41.95M derived: sum of 2 quarters · filed 2013-02-19 | -$61.03M derived: sum of 3 quarters · filed 2013-02-19 | -$60.70M 10-K · filed 2013-02-19 |
| 2010-09-30 | -$22.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$41.20M derived: sum of 2 quarters · filed 2011-11-03 | -$40.88M 10-Q · filed 2011-11-03 | -$61.16M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | -$19.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | -$18.75M 10-Q · filed 2011-08-03 | -$39.04M derived: sum of 3 quarters · filed 2012-02-13 | -$59.18M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | $328.00K 10-Q · filed 2011-05-05 | -$19.96M derived: sum of 2 quarters · filed 2012-02-13 | -$40.10M derived: sum of 3 quarters · filed 2012-02-13 | |
| 2009-12-31 | -$20.28M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | -$40.43M derived: sum of 2 quarters · filed 2012-02-13 | -$58.17M 10-K · filed 2012-02-13 | |
| 2009-09-30 | -$20.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | -$37.89M 10-Q · filed 2010-11-04 | ||
| 2009-06-30 | -$17.75M 10-Q · filed 2010-08-05 | |||
| 2008-12-31 | $66.67M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |